UNC0.F UCB S.A. UNSP.ADR 1/2

Healthcare Biotechnology Frankfurt Exchange
145.00 EUR
Close of Nov 12, 2026
98.50 150.00
Market cap
EUR 55.2B
P/E
25.6x
P/B
4.84x
ROE
14.3%
Dividend yield
0.48%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is UNC0.F undervalued?

Graham number
Price145.00
Graham value61.80
Premium134.6%

UNC0.F trades 134.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

UCB S.A. UNSP.ADR 1/2 fundamental analysis

No fundamental analysis for UCB S.A. UNSP.ADR 1/2 yet.

UCB S.A. UNSP.ADR 1/2 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About UCB S.A. UNSP.ADR 1/2

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs …

Full company profile